Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.63B P/E - EPS this Y -6.30% Ern Qtrly Grth -
Income -219.55M Forward P/E -10.32 EPS next Y 58.80% 50D Avg Chg -
Sales 1.37M PEG -2.61 EPS past 5Y - 200D Avg Chg 18.00%
Dividend N/A Price/Book 4.99 EPS next 5Y 5.00% 52W High Chg -17.00%
Recommedations 1.60 Quick Ratio 3.53 Shares Outstanding 602.80M 52W Low Chg 64.00%
Insider Own 0.09% ROA -32.87% Shares Float 555.88M Beta 0.51
Inst Own 77.97% ROE -72.56% Shares Shorted/Prior 71.51M/69.11M Price 3.20
Gross Margin - Profit Margin - Avg. Volume 5,610,301 Target Price 7.31
Oper. Margin -7,860.88% Earnings Date Oct 31 Volume 2,355,788 Change -0.31%
About Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation News
10/12/24 Is Geron Corporation (GERN) the Best Growth Stock Under $10 to Buy?
10/10/24 Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential?
10/09/24 Geron Corp (GERN) Q2 2024 Earnings Call Highlights: Strong Financial Position Amid Early Rytelo ...
10/09/24 Wall Street Analysts Rate Geron Corporation (GERN) as a Buy Amid Strong Growth Prospects
10/07/24 Geron Corporation (GERN): A Hot Stock to Buy Now
10/03/24 Is Geron Corporation (GERN) the Best NASDAQ Stock Under $5?
10/01/24 High Growth Tech Stocks To Watch This October 2024
09/30/24 When Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)?
09/19/24 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:08 PM Geron Corp. (GERN): Short Seller Sentiment is Bearish on This Cancer Stock
09/12/24 Geron Corp. (GERN): Fast-Growing Penny Stock To Consider
09/12/24 Geron Corporation (NASDAQ:GERN): Hedge Funds Are Bullish On This US Stock to Buy Under $5 Now
09/09/24 Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
09/02/24 High Growth Tech Stocks To Watch In September 2024
08/10/24 Investing in Geron (NASDAQ:GERN) three years ago would have delivered you a 285% gain
08/10/24 Geron Second Quarter 2024 Earnings: Beats Expectations
08/08/24 Geron (GERN) Q2 2024 Earnings Call Transcript
08/08/24 Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Geron: Q2 Earnings Snapshot
08/08/24 Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
GERN Chatroom

User Image Huntlardo Posted - 25 minutes ago

$GERN forth time hitting this 4.14-4.16 range and bouncing off it. this is the floor.

User Image rtornatore13 Posted - 3 hours ago

$GERN weird

User Image Rickster4retirement Posted - 4 hours ago

$GERN Unless this is some type of setup, this downward pressure with approval is really bothersome 👺

User Image bonksofla Posted - 5 hours ago

$GERN sure does look like the powers to be want to close that gap down at around $4.05 before earnings, maybe this week. We will see soon.

User Image signet01 Posted - 6 hours ago

$GERN stinking YH would not publish the following inoffensive comment… ”No one, in their right mind, having held on for some number of years, would let go now, when RYTELO is about to reach its promise to patients and long-term shareholders… “

User Image AxelWiz Posted - 7 hours ago

$GERN idiots shorting a sure thing with fda approval! wow

User Image UnlikelyResult Posted - 8 hours ago

$GERN Where's the next catalyst here?

User Image G101SPM Posted - 8 hours ago

@Cello69 #SYMBOLBOX Hold long position $GERN $4.15 bid. DAC (dollar average cost) $3.30 (3.14.24) carries SPM 86.15 tag to EXIT( $8.50).

User Image G101SPM Posted - 8 hours ago

@Cello69 #SYMBOLBOX Hold long position $GERN $4.15 bid. DAC (dollar average cost) $3.30 (3.14.24) carries SPM 86.15 tag to EXIT( $$8.50).

User Image stefano62 Posted - 8 hours ago

$GERN actually we are really nont able to see two green days in arow........ this is frustrating

User Image patso1964 Posted - 9 hours ago

$GERN this is just ridiculous we are approved and there are people seling for penny

User Image ZoeyTanner Posted - 9 hours ago

The best short in the business $GERN

User Image DAWGNuts Posted - 3 days ago

$GERN there was a huge short position when newly hired Geron execs were hired. Do you think Scarlett and company with punish shorts for helping them get their cheap shares? That's a hard no imo.

User Image Cello69 Posted - 3 days ago

$GERN What's with this pig?

User Image telomerase Posted - 3 days ago

$GERN more competition in the anti-telomerase field, and it's finished Phase 2. Oncolys, a Japanese company: https://www.oncolys.com/en/

User Image DoctrBenway Posted - 3 days ago

@Egerton Dear Dr. Osler: As you're an oncologist dealing with AML, MDS, etc. I thought I'd get your opinions on Rytelo (imetelstat, $GERN) and Xpovio (selinexor, $KPTI). I've also followed if you want to take it to IMs. Best regards, Wm Welch. 😀

User Image Ms_P Posted - 4 days ago

$IOVA $GERN $DAWN getting recognition https://www.linkedin.com/posts/califesciences_introducing-the-finalists-for-the-21st-annual-activity-7249206889547247616-qE40?utm_source=share&utm_medium=member_ios

User Image Millie_Seconds Posted - 4 days ago

$GERN https://finance.yahoo.com/news/geron-corporation-gern-best-stock-133659340.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9yZWNlbnQtcXVvdGVzLw&guce_referrer_sig=AQAAAA4n9Gs80ARcmuy5NymOwkgHL6K0l6I_E-EbxyPbSYcYPJJBCIzQLNU4_6fd6zcEqsHuzSE_PLTGTYad16rqxVZ4waQZCsv-85CLg148MYXIg2Vfik7duJsiY_oGDvS5zIhXcWOexLddzNXu_lckk2cZTvZHv_bqHaDWe8QmdQdV

User Image chrlapp Posted - 4 days ago

$GERN C’mon, EMA. Bring Rytelo to Europe.

User Image DAWGNuts Posted - 4 days ago

$GERN Baker Bros in the building!(Behind the curtains)

User Image Huntlardo Posted - 5 days ago

$GERN shorts are trying hard to keep a cap on this

User Image Huntlardo Posted - 5 days ago

$GERN lowest volume day in a long time

User Image FreshFit Posted - 5 days ago

$GERN buy 4.20 sell at 4.60 has been the cycle lol

User Image Night_Owl_Biotech Posted - 5 days ago

$SWTX is trading at a year to date low after reporting its second quarterly beat in a row 2 months ago. SWTX shot up after reporting the Q2 2024 beat but is off roughly 28% since (over the last 6-7 weeks). Investors may want to consider SWTX's 2 near-term therapies both of which are anticipated to be Blockbusters (per SWTX's CEO & BofA analysts). We are not qualified to opine on these estimates so we recommend investors research for themselves. Considering Big Pharma's are losing key patents, many believe M&A will eventually pick up. As near as we can tell, SWTX is one of a few high quality targets with meaningful near term revenue pot'l. SWTX trades for ~2.0X FY28 (Year 4) analyst consensus revenue estimates. Centerview Partners' review per IMGN's 14A filing notes median peer Year 4 M&A multiples at 6.0X. SWTX may or may not be a peer. Other comm'l stage oncology focused bios are trading at lows (i.e. $IOVA, $DAWN, $GERN $URGN). This is not investment advice but is it time?

User Image patso1964 Posted - 5 days ago

$GERN Gern state that they expect to spend $280 Mil next FY 800 patients at 365K/y is $792 Mil this stock is just getting ready to make $$$$$$$$$$$$$$$$$$$$$$$$$$

User Image Mail_Dog Posted - 5 days ago

$GERN While SHs continue to wait for EMA-MAA…

User Image patso1964 Posted - 5 days ago

$GERN pure manipulation someone is keeping this down

User Image Huntlardo Posted - 5 days ago

$GERN https://workforcenow.adp.com/mascsr/default/mdf/recruitment/recruitment.html?cid=a69f1432-af4c-471b-88c8-44c7c81587aa&ccId=19000101_000001&type=JS&lang=en_US&jobId=519269 • Owns and manages the publication planning process and Phase 4 program identification, prioritization, and reviews with cross-functional teams Wonder if we get a conditional approval with MF and phase four study too confirm. Language in this job description would lead one to believe so. BP pulled this link

User Image KingCryptoMan Posted - 5 days ago

$GERN For everyone living in the Tampa Bay region like me - Now is the time for prayers. The beach communities are a catastrophe from hurricane Helene. Homes and businesses destroyed. Milton is barreling down. I wish everyone God Speed.

User Image Percy619 Posted - 6 days ago

$GERN i can't believe i'm up a hundred thirty nine percent in a year and there's not enough action.

Analyst Ratings
Leerink Partners Outperform Sep 9, 24
Needham Buy Aug 9, 24
Needham Buy Jul 26, 24
Barclays Overweight Jun 11, 24
Barclays Overweight Jun 10, 24
Stifel Buy Jun 10, 24
Needham Buy Jun 7, 24
Wedbush Outperform Jun 7, 24
Needham Buy May 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
O'Farrell Elizabeth G. Director Director Aug 24 Buy 2.28 13,186 30,064 26,220 08/24/23
LAWLIS V BRYAN Director Director May 11 Sell 3 35,000 105,000 05/11/23
LAWLIS V BRYAN Director Director May 11 Option 1.1 35,000 38,500 35,000 05/11/23
Molineaux Susan Director Director May 01 Sell 2.48 35,000 86,800 05/01/23
Molineaux Susan Director Director May 01 Option 1.1 35,000 38,500 35,000 05/01/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Feb 09 Sell 3.03 384,719 1,165,699 02/10/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Feb 09 Option 1.51 150,000 226,500 384,719 02/10/23
Bloom Olivia Kyusuk EVP, Chief Financial.. EVP, Chief Financial Officer Feb 08 Sell 3.08 400,000 1,232,000 74,588 02/10/23
Bloom Olivia Kyusuk EVP, Chief Financial.. EVP, Chief Financial Officer Feb 08 Option 1.51 400,000 604,000 474,588 02/10/23
SCARLETT JOHN A Chairman, President.. Chairman, President and CEO Feb 08 Sell 3.04 1,340,000 4,073,600 02/10/23
SCARLETT JOHN A Chairman, President.. Chairman, President and CEO Feb 08 Option 1.5 1,340,000 2,010,000 446,668 02/10/23
EASTHAM KARIN Director Director Jan 13 Option 1.10 35,000 38,500 109,047 01/17/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Sep 12 Option 1.7 234,719 399,022 234,719 09/14/22
EASTHAM KARIN Director Director Apr 20 Option 1.41 35,000 49,350 74,047 04/21/22